---
title: "2026 Chinese Medical Association Guideline: Clinical Diagnosis and Treatment of Lung Cancer"
id: "pubmed-42763208"
canonical_url: "https://medichelpline.com/clinical-feed/pubmed-42763208"
content_type: "clinical_feed_article"
specialty: "Oncology"
source_name: "PubMed / NCBI"
source_url: "https://pubmed.ncbi.nlm.nih.gov/42763208/"
doi: "10.3760/cma.j.cn112137-20260511-01255"
published_at: "2026-09-22T00:00:00.000Z"
evidence_level: "Journal Article"
license: "CC-BY-NC-4.0 / Informational Use"
---
# 2026 Chinese Medical Association Guideline: Clinical Diagnosis and Treatment of Lung Cancer
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/pubmed-42763208
- **Specialty:** [Oncology](https://medichelpline.com/clinical-feed/oncology.md)
- **Primary Source:** PubMed / NCBI
- **Source URL:** [Original Journal Publication](https://pubmed.ncbi.nlm.nih.gov/42763208/)
- **DOI:** [10.3760/cma.j.cn112137-20260511-01255](https://doi.org/10.3760%2Fcma.j.cn112137-20260511-01255)
- **Published At:** 2026-09-22T00:00:00.000Z
- **Evidence Rating:** Journal Article
## Executive GIST (TL;DR)
- The Oncology Society of the Chinese Medical Association issued the "Guideline for clinical diagnosis and treatment of lung cancer (2026 edition)" to standardize lung cancer prevention, diagnosis, treatment, and follow-up in China. The guideline was developed by multidisciplinary experts through a consensus process. - The 2026 edition updates and refines the 2025 guideline across screening, pathology, molecular testing, treatment, and follow-up, emphasizing applicability to clinical practice in China and alignment with regulatory approvals. - Screening: quality control requirements for **low-dose computed tomography** (LDCT) screening are further detailed; the guideline adds guidance on **opportunistic screening** and the role and scope of **artificial intelligence** technologies in screening. - Pathology and testing: recommendations for **molecular pathological testing** were expanded based on recent clinical evidence and new indications approved by the **NMPA**; several new gene-testing recommendations were added. - Treatment updates: perioperative **neoadjuvant** and **adjuvant** regimens for non–small cell lung cancer (NSCLC) were revised to reflect newly approved drugs and indications. Consolidation **immunotherapy** options after concurrent or sequential chemoradiotherapy for unresectable stage III NSCLC were added. - Systemic therapy refinements: first-line and subsequent-line strategies for advanced **EGFR**-mutant disease were further specified. Recommendations for molecular subtypes including **ALK** fusion, **KRAS G12C**, **HER-2** mutations, and **MET** amplification were updated consistent with newly approved agents. - The guideline uses **NMPA-approved indications** as the core principle and focuses on drugs accessible in China, while integrating international guideline recommendations and current Chinese clinical practice. - Scope: the document covers lung cancer screening, diagnosis, pathology, genetic and biomarker testing, treatment modalities (surgery, radiation, systemic therapy), and follow-up, aimed at clinicians across levels and related specialties (radiology, laboratory medicine). - Administrative details reported: publication in Zhonghua Yi Xue Za Zhi (2026 Sep 22;106(35):3687–3723), DOI 10.3760/cma.j.cn112137-20260511-01255, PubMed PMID 42763208. The authors declare no conflicts of interest.
## Clinical Analysis & Structured Key Points
Clipboard, Search History, and several other advanced features are temporarily unavailable. [ Skip to main page content ](https://pubmed.ncbi.nlm.nih.gov/42763208/#article-details) ![U.S. flag](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/favicons/favicon-57.png) An official website of the United States government Here's how you know ![Dot gov](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-dot-gov.svg) **The .gov means it’s official.** Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site. ![Https](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-https.svg) **The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. [ ![NIH NLM Logo](https://cdn.ncbi.nlm.nih.gov/coreutils/nwds/img/logos/AgencyLogo.svg) ](https://www.ncbi.nlm.nih.gov/) [Log in](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42763208%2F) Show account info Close #### Account Logged in as: **username** * [Dashboard](https://www.ncbi.nlm.nih.gov/myncbi/) * [Publications](https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/) * [Account settings](https://www.ncbi.nlm.nih.gov/account/settings/) * [Log out](https://www.ncbi.nlm.nih.gov/account/signout/?back_url=https%3A//pubmed.ncbi.nlm.nih.gov/42763208/) [Access keys](https://www.ncbi.nlm.nih.gov/guide/browsers/#ncbi_accesskeys) [NCBI Homepage](https://www.ncbi.nlm.nih.gov) [MyNCBI Homepage](https://pubmed.ncbi.nlm.nih.gov/myncbi/) [Main Content](https://pubmed.ncbi.nlm.nih.gov/42763208/#maincontent) [Main Navigation](https://pubmed.ncbi.nlm.nih.gov/42763208/) [ ![pubmed logo](https://cdn.ncbi.nlm.nih.gov/pubmed/c24ab723-7c80-48cd-9c68-022ded852586/core/images/pubmed-logo-blue.svg) ](https://pubmed.ncbi.nlm.nih.gov/) [ ](https://pubmed.ncbi.nlm.nih.gov/42763208/ "Show search bar") Search: [](https://pubmed.ncbi.nlm.nih.gov/42763208/ "Clear search input")Search [Advanced](https://pubmed.ncbi.nlm.nih.gov/advanced/) [ Clipboard ](https://pubmed.ncbi.nlm.nih.gov/clipboard/) [ User Guide ](https://pubmed.ncbi.nlm.nih.gov/help/) Save Email Send to * [ Clipboard ](https://pubmed.ncbi.nlm.nih.gov/42763208/) * [My Bibliography](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42763208%2F%23open-bibliography-panel) * [Collections](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42763208%2F%23open-collections-panel) * [Citation manager](https://pubmed.ncbi.nlm.nih.gov/42763208/) Display options Display options Format Abstract PubMed PMID ## Save citation to file Format: Summary (text) PubMed PMID Abstract (text) CSV Create file Cancel ## Email citation Email address has not been verified. Go to [ My NCBI account settings ](https://account.ncbi.nlm.nih.gov/settings/) to confirm your email and then refresh this page. To: Subject: Body: Format: Summary Summary (text) Abstract Abstract (text) MeSH and other data Send email Cancel ### Add to Collections * Create a new collection * Add to an existing collection Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/42763208/) Add Cancel ### Add to My Bibliography * My Bibliography Unable to load your delegates due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/42763208/) Add Cancel ## Your saved search Name of saved search: Search terms: [Test search terms](https://pubmed.ncbi.nlm.nih.gov/42763208/) Would you like email updates of new search results? Saved Search Alert Radio Buttons * Yes * No Email: ([change](https://www.ncbi.nlm.nih.gov/account/settings/)) Frequency: Monthly Weekly Daily Which day? The first Sunday The first Monday The first Tuesday The first Wednesday The first Thursday The first Friday The first Saturday The first day The first weekday Which day? Sunday Monday Tuesday Wednesday Thursday Friday Saturday Report format: Summary Summary (text) Abstract Abstract (text) PubMed Send at most: 1 item 5 items 10 items 20 items 50 items 100 items 200 items Send even when there aren't any new results Optional text in email: Save Cancel ## Create a file for external citation management software Create file Cancel ## Your RSS Feed Name of RSS Feed: Number of items displayed: 5 10 15 20 50 100 Create RSS Cancel RSS Link Copy ### Full text links [![Chinese Medical Association Publishing House Ltd. full text link](https://cdn.ncbi.nlm.nih.gov/corehtml/query/egifs/https:--www.medjournals.cn-CMAPH-Linkout-logo.png) Chinese Medical Association Publishing House Ltd. ](https://www.yiigle.com/LinkIn.do?linkin_type=pubmed&DOI=10.3760/cma.j.cn112137-20260511-01255 "See full text options at Chinese Medical Association Publishing House Ltd.") [ Full text links ](https://pubmed.ncbi.nlm.nih.gov/42763208/) ### Actions Cite Collections Add to Collections * Create a new collection * Add to an existing collection Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/42763208/) Add Cancel Permalink Permalink Copy Display options Display options Format Abstract PubMed PMID ### Page navigation * [ Title & authors ](https://pubmed.ncbi.nlm.nih.gov/42763208/#heading) * [ Abstract ](https://pubmed.ncbi.nlm.nih.gov/42763208/#abstract) * [ Conflict of interest statement ](https://pubmed.ncbi.nlm.nih.gov/42763208/#conflict-of-interest) * [Similar articles](https://pubmed.ncbi.nlm.nih.gov/42763208/#similar) * [ Publication types ](https://pubmed.ncbi.nlm.nih.gov/42763208/#publication-types) * [ MeSH terms ](https://pubmed.ncbi.nlm.nih.gov/42763208/#mesh-terms) * [Related information](https://pubmed.ncbi.nlm.nih.gov/42763208/#related-links) * [ LinkOut - more resources ](https://pubmed.ncbi.nlm.nih.gov/42763208/#linkout) Title & authors Abstract Conflict of interest statement Similar articles Publication types MeSH terms Related information LinkOut - more resources Practice Guideline Zhonghua Yi Xue Za Zhi Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Zhonghua+Yi+Xue+Za+Zhi%22%5Bjour%5D&sort=date&sort_order=desc) * [ Search in NLM Catalog ](https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Zhonghua+Yi+Xue+Za+Zhi%22%5BTitle+Abbreviation%5D) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42763208/) . 2026 Sep 22;106(35):3687-3723. doi: 10.3760/cma.j.cn112137-20260511-01255. # [Oncology Society of Chinese Medical Association guideline for clinical diagnosis and treatment of lung cancer (2026 edition)] [Article in Chinese] [Oncology Society of Chinese Medical Association](https://pubmed.ncbi.nlm.nih.gov/?term=Oncology+Society+of+Chinese+Medical+Association%5BCorporate+Author%5D) * PMID: **42763208** * DOI: [ 10.3760/cma.j.cn112137-20260511-01255 ](https://doi.org/10.3760/cma.j.cn112137-20260511-01255) Item in Clipboard Practice Guideline # [Oncology Society of Chinese Medical Association guideline for clinical diagnosis and treatment of lung cancer (2026 edition)] [Article in Chinese] Oncology Society of Chinese Medical Association. Zhonghua Yi Xue Za Zhi. 2026. Show details Display options Display options Format Abstract PubMed PMID Zhonghua Yi Xue Za Zhi Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Zhonghua+Yi+Xue+Za+Zhi%22%5Bjour%5D&sort=date&sort_order=desc) * [ Search in NLM Catalog ](https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Zhonghua+Yi+Xue+Za+Zhi%22%5BTitle+Abbreviation%5D) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42763208/) . 2026 Sep 22;106(35):3687-3723. doi: 10.3760/cma.j.cn112137-20260511-01255. ### Author [Oncology Society of Chinese Medical Association](https://pubmed.ncbi.nlm.nih.gov/?term=Oncology+Society+of+Chinese+Medical+Association%5BCorporate+Author%5D) * PMID: **42763208** * DOI: [ 10.3760/cma.j.cn112137-20260511-01255 ](https://doi.org/10.3760/cma.j.cn112137-20260511-01255) Item in Clipboard Full text links Cite Display options Display options Format Abstract PubMed PMID ## Abstract in [ English, ](https://pubmed.ncbi.nlm.nih.gov/42763208/#eng-abstract) [ Chinese ](https://pubmed.ncbi.nlm.nih.gov/42763208/#zho-abstract) To further standardize the prevention and management of lung cancer in China, improve the level of diagnosis and treatment, enhance patient prognosis, and provide evidence-based professional recommendations for clinical practitioners at all levels, the Oncology Society of Chinese Medical Association organized experts from respiratory medicine, medical oncology, thoracic surgery, radiation oncology, radiology, and pathology to develop the "Oncology Society of Chinese Medical Association guideline for clinical diagnosis and treatment of lung cancer (2026 edition)" through a consensus conference. Compared with the 2025 edition, the 2026 edition incorporates updates and refinements in several aspects. In the lung cancer screening section, quality control requirements for low-dose computed tomography screening have been further detailed, and the introduction and scope of application of opportunistic screening and artificial intelligence technologies in lung cancer screening have been added. In the pathology section, on the basis of the latest clinical research findings and newly approved indications by the National Medical Products Administration (NMPA), the recommendations for molecular pathological testing have been supplemented, with several new gene testing-related recommendations added. In the treatment section, perioperative neoadjuvant and adjuvant treatment regimens for non-small cell lung cancer have been updated according to newly approved drugs and indications; additional options for consolidation immunotherapy after concurrent or sequential chemoradiotherapy for unresectable stage Ⅲ non-small cell lung cancer have been incorporated; and first-line and subsequent-line treatment strategies for patients with advanced epidermal growth factor receptor (EGFR)-mutations have been further refined. In addition, treatment recommendations for patients with non-small cell lung cancer harboring molecular subtypes such as anaplastic lymphoma kinase (ALK) fusion, KRAS G12C mutation, human epidermal growth factor receptor 2 (HER-2) mutations, and MET amplification have also been updated based on the approval of novel agents. This guideline adheres to NMPA-approved indications as the core principle, is grounded in drugs practically available in China and integrates recommendations from international guidelines as well as the current status of clinical practice in China. It synthesizes the latest evidence-based medical advances in recent years covering lung cancer screening, diagnosis, pathology, genetic testing, immunologic and molecular biomarker testing, treatment modalities, and follow-up, with the aim of providing reasonable and practical recommendations for clinicians at all levels, as well as professionals in radiology, laboratory medicine, and related disciplines. 为进一步规范中国肺癌的防治措施、提高肺癌的诊疗水平、改善患者的预后、为各级临床医务人员提供专业的循证医学建议，中华医学会肿瘤学分会组织呼吸内科、肿瘤内科、胸外科、放射治疗科、影像科和病理科专家，经过共识会议制订了《中华医学会肿瘤学分会肺癌临床诊疗指南（2026版）》。与2025版指南相比，2026版指南在多个方面进行了更新和完善。肺癌筛查部分进一步细化了低剂量螺旋CT筛查的质量控制要求，并增加了机会性筛查及人工智能技术在肺癌筛查中的应用介绍和适用范围。病理诊断部分结合最新临床研究结果及中国国家药品监督管理局（NMPA）新批准适应证，对分子病理检测内容进行了补充，新增了多个基因检测相关建议。治疗部分根据新获批的药物和适应证，对围手术期非小细胞肺癌的新辅助及辅助治疗方案进行了更新；对不可切除Ⅲ期非小细胞肺癌同步或序贯放化疗后的免疫巩固治疗选择进行了补充；对晚期表皮生长因子受体（EGFR）基因突变患者一线及后线治疗策略进行了完善。此外，针对间变性淋巴瘤激酶（ALK）融合、KRAS G12C突变、人表皮生长因子受体2（HER-2）基因突变及MET扩增等分子亚型的非小细胞肺癌患者，也根据新型药物获批情况更新了相应治疗推荐。该指南以NMPA批准适应证为核心原则，以中国实际可应用的药品为基础，结合国际指南推荐意见和中国临床实践现状，整合近年来肺癌筛查、诊断、病理、基因检测、免疫分子标志物检测和治疗手段以及随访等诊治方面的最新循证医学证据，旨在为各级临床医师、影像、检验等专业人员提供合理的推荐建议。. [PubMed Disclaimer](https://pubmed.ncbi.nlm.nih.gov/disclaimer/) ## Conflict of interest statement 所有作者声明不存在利益冲突 ## Similar articles * [ [Chinese Medical Association guideline for clinical diagnosis and treatment of lung cancer (2025 edition)]. ](https://pubmed.ncbi.nlm.nih.gov/40796288/) Oncology Society of Chinese Medical Association.Oncology Society of Chinese Medical Association.Zhonghua Zhong Liu Za Zhi. 2025 Sep 23;47(9):769-810. doi: 10.3760/cma.j.cn112152-20250511-00215.Zhonghua Zhong Liu Za Zhi. 2025.PMID: 40796288Chinese. * [ [Chinese Medical Association guideline for clinical diagnosis and treatment of lung cancer (2025 edition)]. ](https://pubmed.ncbi.nlm.nih.gov/40796286/) Oncology Society of Chinese Medical Association.Oncology Society of Chinese Medical Association.Zhonghua Yi Xue Za Zhi. 2025 Sep 9;105(34):2918-2959. doi: 10.3760/cma.j.cn112137-20250511-01152.Zhonghua Yi Xue Za Zhi. 2025.PMID: 40796286Chinese. * [ [Chinese Medical Association guideline for clinical diagnosis and treatment of lung cancer (2023 edition)]. ](https://pubmed.ncbi.nlm.nih.gov/37460438/) Oncology Society of Chinese Medical Association; Chinese Medical Association Publishing House.Oncology Society of Chinese Medical Association, et al.Zhonghua Zhong Liu Za Zhi. 2023 Jul 23;45(7):539-574. doi: 10.3760/cma.j.cn112152-20230510-00200.Zhonghua Zhong Liu Za Zhi. 2023.PMID: 37460438Chinese. * [ [Chinese Medical Association guideline for clinical diagnosis and treatment of lung cancer (2024 edition)]. ](https://pubmed.ncbi.nlm.nih.gov/39045625/) Oncology Society of Chinese Medical Association.Oncology Society of Chinese Medical Association.Zhonghua Zhong Liu Za Zhi. 2024 Sep 23;46(9):805-843. doi: 10.3760/cma.j.cn112152-20240510-00189.Zhonghua Zhong Liu Za Zhi. 2024.PMID: 39045625Chinese. * [ [Chinese Medical Association guideline for clinical diagnosis and treatment of lung cancer (2024 edition)]. ](https://pubmed.ncbi.nlm.nih.gov/39193605/) Oncology Society of Chinese Medical Association.Oncology Society of Chinese Medical Association.Zhonghua Yi Xue Za Zhi. 2024 Sep 3;104(34):3175-3213. doi: 10.3760/cma.j.cn112137-20240511-01092.Zhonghua Yi Xue Za Zhi. 2024.PMID: 39193605Chinese. [ See all similar articles ](https://pubmed.ncbi.nlm.nih.gov/?linkname=pubmed_pubmed&from_uid=42763208) ## Publication types * Practice Guideline Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Practice+Guideline%22%5Bpt%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Practice+Guideline) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42763208/) * English Abstract Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22English+Abstract%22%5Bpt%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=English+Abstract) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42763208/) ## MeSH terms * China Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22China%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=China) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42763208/) * Humans Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Humans%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Humans) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42763208/) * Lung Neoplasms* / diagnosis Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Lung+Neoplasms%2Fdiagnosis%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Lung+Neoplasms) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42763208/) * Lung Neoplasms* / therapy Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Lung+Neoplasms%2Ftherapy%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Lung+Neoplasms) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42763208/) * Medical Oncology Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Medical+Oncology%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Medical+Oncology) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42763208/) * Societies, Medical Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Societies%2C+Medical%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Societies%2C+Medical) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42763208/) ## Related information * [ MedGen ](https://www.ncbi.nlm.nih.gov/medgen?linkname=pubmed_medgen&from_uid=42763208 "Related information in MedGen") ## LinkOut - more resources * ### Full Text Sources * [ Chinese Medical Association Publishing House Ltd. ](https://www.yiigle.com/LinkIn.do?linkin_type=pubmed&DOI=10.3760/cma.j.cn112137-20260511-01255) * ### Medical * [ MedlinePlus Health Information ](https://medlineplus.gov/lungcancer.html) * ### Research Materials * [ NCI CPTC Antibody Characterization Program ](https://antibodies.cancer.gov/detail/CPTC-EGFR-8) * ### Miscellaneous * [ NCI CPTAC Assay Portal ](https://assays.cancer.gov/CPTAC-1550) **Full text links** [x] [![Chinese Medical Association Publishing House Ltd. full text link](https://cdn.ncbi.nlm.nih.gov/corehtml/query/egifs/https:--www.medjournals.cn-CMAPH-Linkout-logo.png) Chinese Medical Association Publishing House Ltd. ](https://www.yiigle.com/LinkIn.do?linkin_type=pubmed&DOI=10.3760/cma.j.cn112137-20260511-01255 "See full text options at Chinese Medical Association Publishing House Ltd.") [x] Cite Copy Download .nbib .nbib Format: AMA APA MLA NLM **Send To** * [Clipboard](https://pubmed.ncbi.nlm.nih.gov/42763208/) * [Email](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42763208%2F%23open-email-panel) * [Save](https://pubmed.ncbi.nlm.nih.gov/42763208/) * [My Bibliography](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42763208%2F%23open-bibliography-panel) * [Collections](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42763208%2F%23open-collections-panel) * [Citation Manager](https://pubmed.ncbi.nlm.nih.gov/42763208/) [x] NCBI Literature Resources [MeSH](https://www.ncbi.nlm.nih.gov/mesh/) [PMC](https://www.ncbi.nlm.nih.gov/pmc/) [Bookshelf](https://www.ncbi.nlm.nih.gov/books) [Disclaimer](https://pubmed.ncbi.nlm.nih.gov/disclaimer/) The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited. Follow NCBI [ Twitter ](https://twitter.com/ncbi) [ Facebook ](https://www.facebook.com/ncbi.nlm) [ LinkedIn ](https://www.linkedin.com/company/ncbinlm) [ GitHub ](https://github.com/ncbi) [ ](https://ncbiinsights.ncbi.nlm.nih.gov/) [Connect with NLM](https://www.nlm.nih.gov/socialmedia/index.html) * [ Twitter ](https://twitter.com/NLM_NIH) * [ SM-Facebook ](https://www.facebook.com/nationallibraryofmedicine) * [ SM-Youtube ](https://www.youtube.com/user/NLMNIH) National Library of Medicine [8600 Rockville Pike Bethesda, MD 20894](https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/@38.9959508,-77.101021,17z/data=!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb:0x19156f88b27635b8!8m2!3d38.9959508!4d-77.0988323) [Web Policies](https://www.nlm.nih.gov/web_policies.html) [FOIA](https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office) [HHS Vulnerability Disclosure](https://www.hhs.gov/vulnerability-disclosure-p
## Related Clinical Research

- [Blood test trends versus single abnormal results to detect cancer in patients with unexpected weig](https://medichelpline.com/clinical-feed/plos-medicine-1-blood-test-trend-versus-single-threshold-abnormality-to-discriminate-cancer.md)
- [Blood test trends versus single abnormal results to detect cancer in patients with unexpected weig](https://medichelpline.com/clinical-feed/pubmed-42752402.md) (DOI: 10.1371/journal.pmed.1004956)
- [Increased 1-Year Risk of Ischemic Stroke After Invasive Cancer Diagnosis: Nationwide Cohort Study](https://medichelpline.com/clinical-feed/pubmed-42706874.md) (DOI: 10.1002/cncr.70536)
- [MYC–MIZ1 Enhancer Complexes Regulate Neuroendocrine Identity in Small Cell Lung Cancer](https://medichelpline.com/clinical-feed/biorxiv-7-myc-miz1-complexes-at-enhancers-tune-neuroendocrine-identity-of-small-cell-lung.md)
- [CXCR4 and PD-1 blockade overcomes stroma-driven T-cell exclusion and exhaustion in PDAC 3D models](https://medichelpline.com/clinical-feed/frontiers-in-immunology-17-targeting-stroma-mediated-t-cell-exclusion-and-functional-exhaustion-in.md)

## Navigation
- [← Back to Oncology Feed](https://medichelpline.com/clinical-feed/oncology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.